Northern Trust’s NRX Pharmaceuticals NRXP Stock Holding History

Northern Trust’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$257K	Buy	62,951 +19,482	+45%	+$64.4K	﹤0.01%	3859
2026 Q1	$92.6K	Buy	43,469 +14,522	+50%	+$29.3K	﹤0.01%	4127
2025 Q4	$78.4K	Buy	28,947 +346	+1%	+$929	﹤0.01%	4184
2025 Q3	$94.4K	Hold	28,601	–	–	﹤0.01%	4153
2025 Q2	$93.2K	Hold	28,601	–	–	﹤0.01%	4126
2025 Q1	$58.6K	Buy	+28,601	New	+$80.6K	﹤0.01%	4211
2024 Q2	–	Sell	-7,500	Closed	-$35.4K	–	4452
2024 Q1	$35.4K	Hold	7,500	–	–	﹤0.01%	4274
2023 Q4	$34.5K	Hold	7,500	–	–	﹤0.01%	4296
2023 Q3	$19.5K	Hold	7,500	–	–	﹤0.01%	4335
2023 Q2	$36.3K	Buy	7,500 +376	+5%	+$2.26K	﹤0.01%	4292
2023 Q1	$47K	Buy	7,124 +1,264	+22%	+$12.8K	﹤0.01%	4282
2022 Q4	$65K	Hold	5,860	–	–	﹤0.01%	4216
2022 Q3	$43K	Hold	5,860	–	–	﹤0.01%	4365
2022 Q2	$35K	Hold	5,860	–	–	﹤0.01%	4508
2022 Q1	$144K	Buy	5,860 +2,232	+62%	+$72.6K	﹤0.01%	4238
2021 Q4	$173K	Buy	+3,628	New	+$262K	﹤0.01%	4247
2021 Q3	–	Sell	-13,063	Closed	-$1.52M	–	4719
2021 Q2	$1.52M	Buy	+13,063	New	+$3.45M	﹤0.01%	3432

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust's NRXP Position: Q2 2026 in Review

Northern Trust increased its NRX Pharmaceuticals (NRXP) stake by 45% in Q2 2026, buying an estimated $64.4K and bringing the position to 62,951 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #3859.

Northern Trust first reported a position in NRXP in Q2 2021 and has held it in 17 quarters since. The position peaked at $1.52M in Q2 2021. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

Northern Trust held 62,951 shares of NRX Pharmaceuticals worth $257K as of Q2 2026.
Northern Trust bought 19,482 NRX Pharmaceuticals shares in Q2 2026, an estimated $64.4K.
NRX Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3859 holding.
Northern Trust first reported a position in NRX Pharmaceuticals in Q2 2021 and has held it in 17 quarters since.
Northern Trust's NRX Pharmaceuticals position peaked at $1.52M in Q2 2021.
46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.